Literature DB >> 21633344

The male genital tract is not a pharmacological sanctuary from efavirenz.

L B Avery1, R P Bakshi, Y J Cao, C W Hendrix.   

Abstract

Many antiretroviral (ARV) drugs have large blood plasma-to-seminal plasma (BP/SP) concentration ratios. Concern exists that these drugs do not adequately penetrate the male genital tract (MGT), resulting in the MGT becoming a "pharmacological sanctuary" from these agents, with ineffective MGT concentrations despite effective blood concentrations. Efavirenz (EFV) is the most highly protein-bound ARV drug, with >99% binding in blood plasma and the largest BP/SP total EFV concentration ratio, reportedly ranging from 11 to 33. To evaluate protein binding as an explanation for the differences between the drug concentrations in blood and semen, we developed a novel ultrafiltration method, corrected for the duration of centrifugation, to measure protein binding in the two matrices. In six subjects, protein-free EFV concentrations were the same in blood and semen; the median (interquartile range (IQR)) protein-free EFV SP/BP ratio was 1.21 (0.99-1.35); EFV protein binding was 99.82% (99.79-99.86) in BP and 95.26% (93.24-96.67) in SP. This shows that the MGT is not a sanctuary from EFV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21633344      PMCID: PMC3215581          DOI: 10.1038/clpt.2011.99

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

Review 2.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Separation procedures used to reveal and follow drug-protein binding.

Authors:  B Sebille; R Zini; C V Madjar; N Thuaud; J P Tillement
Journal:  J Chromatogr       Date:  1990-10-12

4.  A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma.

Authors:  Lindsay B Avery; Teresa L Parsons; David J Meyers; Walter C Hubbard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-08       Impact factor: 3.205

5.  Binding of anti-HIV drugs to human serum albumin.

Authors:  Alessio Bocedi; Stefania Notaril; Pasquale Narciso; Alessandro Bolli; Mauro Fasano; Paolo Ascenzi
Journal:  IUBMB Life       Date:  2004-10       Impact factor: 3.885

Review 6.  Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment.

Authors:  Y-J Cao; C W Hendrix
Journal:  Clin Pharmacol Ther       Date:  2007-10-05       Impact factor: 6.875

7.  The importance of plasma protein binding in drug discovery.

Authors:  George L Trainor
Journal:  Expert Opin Drug Discov       Date:  2007-01       Impact factor: 6.098

8.  Potential effect of the plasma on drug distribution.

Authors:  B K Martin
Journal:  Nature       Date:  1965-07-17       Impact factor: 49.962

9.  A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate.

Authors:  Themba T Ndovi; Teresa Parsons; Leena Choi; Brian Caffo; Charles Rohde; Craig W Hendrix
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

Review 10.  Protein binding in antiretroviral therapies.

Authors:  Marta Boffito; David J Back; Terrence F Blaschke; Malcolm Rowland; Richard J Bertz; John G Gerber; Veronica Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2003-09       Impact factor: 2.205

View more
  13 in total

Review 1.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

2.  Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.

Authors:  L B Avery; N Sacktor; J C McArthur; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.

Authors:  Lindsay B Avery; Jennifer L VanAusdall; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-11-19       Impact factor: 3.922

Review 4.  Redefining the viral reservoirs that prevent HIV-1 eradication.

Authors:  Evelyn Eisele; Robert F Siliciano
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

5.  Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

Authors:  Lindsay B Avery; Melissa A Zarr; Rahul P Bakshi; Robert F Siliciano; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-22       Impact factor: 2.205

6.  Localization of multidrug resistance-associated proteins along the blood-testis barrier in rat, macaque, and human testis.

Authors:  David M Klein; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

7.  Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo.

Authors:  Jennifer L Welch; Hussein Kaddour; Lee Winchester; Courtney V Fletcher; Jack T Stapleton; Chioma M Okeoma
Journal:  J Acquir Immune Defic Syndr       Date:  2020-01-01       Impact factor: 3.771

8.  Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.

Authors:  Nittaya Phanuphak; Nipat Teeratakulpisarn; Frits van Griensven; Nitiya Chomchey; Suteeraporn Pinyakorn; James Lk Fletcher; Rapee Trichavaroj; Supanit Pattanachaiwit; Nelson Michael; Praphan Phanuphak; Jerome H Kim; Jintanat Ananworanich
Journal:  J Int AIDS Soc       Date:  2015-05-07       Impact factor: 5.396

9.  Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Authors:  Sam Nightingale; Tran Thi Hong Chau; Martin Fisher; Mark Nelson; Alan Winston; Laura Else; Daniel F Carr; Steven Taylor; Andrew Ustianowski; David Back; Munir Pirmohamed; Tom Solomon; Jeremy Farrar; M Estée Törok; Saye Khoo
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.

Authors:  Natalia Mast; Peter Verwilst; Clayton J Wilkey; F Peter Guengerich; Irina A Pikuleva
Journal:  J Med Chem       Date:  2019-11-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.